Investment Rating - The investment rating for the company is "Buy" and is maintained [10]. Core Insights - The company achieved revenue, net profit attributable to the parent, and net profit excluding non-recurring items of 1.228 billion, 136 million, and 111 million yuan respectively for the first three quarters of 2025, representing year-on-year growth of 16.66%, 15.21%, and 19.78% [2][6]. - In Q3 2025, the company reported revenue, net profit attributable to the parent, and net profit excluding non-recurring items of 386 million, 51 million, and 41 million yuan, with year-on-year growth of 10.49%, 11.43%, and 11.03% [2][6]. - The company is experiencing steady revenue growth in Q3, with stable profitability year-on-year, and the effects of proactive cost control are beginning to show [7]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.228 billion yuan, a year-on-year increase of 16.66% [2][6]. - Q3 2025 saw revenue of 386 million yuan, reflecting a year-on-year growth of 10.49% [2][6]. - The net profit attributable to the parent for the first three quarters was 136 million yuan, up 15.21% year-on-year [2][6]. Cost Management - The company has successfully reduced sales expenses by 15.9% year-on-year in Q3, contributing to stable profitability [7]. - The gross profit margin in Q3 saw a slight year-on-year increase of 0.1%, indicating stable profitability [7]. Product and Channel Strategy - The company is optimizing its product structure and expanding channels, with toothpaste sales expected to grow by 5% year-on-year in 2024, alongside a 10% increase in average price [8]. - The "7 Days Repair" series is expected to drive price increases through functional upgrades and marketing strategies [8]. - The company is leveraging e-commerce channels for brand exposure and market reshaping, with significant sales growth on platforms like Douyin [8]. Future Outlook - The company is projected to achieve net profits of 189 million, 243 million, and 305 million yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings ratios of 36, 28, and 22 times [7].
登康口腔（001328）：2025前Q3点评：持续成长，盈利稳健